SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...
Credit: Getty Images. Adding everolimus to adjuvant endocrine therapy does not improve survival for patients with HR+, HER2- breast cancer. Adding 1 year of everolimus to standard adjuvant endocrine ...
At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and ...
Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results